The Male Vitality Protocol: Fertility and Sexual Function Beyond Testosterone

Key Takeaways

The phrase "male vitality" sells a great many products, nearly all of which are testosterone stacks under a different label. Testosterone is one variable. It is not the same variable as sperm count, and it is not the same variable as sexual desire — maca raised desire without touching testosterone, and testosterone replacement raises the hormone while shutting sperm production down entirely.

This protocol is built for the outcome set that the testosterone stacks do not serve: fertility and sexual function. It has three layers, one twelve-week schedule, a single judgement point, and a clear statement of what it leaves out and why. The condensed version with doses is The Male Vitality Protocol; this is the reasoning.

First, the Things That Outrank Every Layer

A urologist before a capsule. Male infertility has anatomical, genetic and hormonal causes that no supplement addresses, and one of them is common and correctable. A varicocele — a dilated venous plexus around the testis — is the most frequent correctable finding in infertile men, and a 2023 meta-analysis of 16 studies compared 1,424 men who had it repaired with 996 who did not: sperm concentration, total count, progressive motility, total motility and normal morphology were all significantly better after repair (concentration SMD 1.739, progressive motility SMD 3.301; both P < 0.01). Obstructive azoospermia, Klinefelter syndrome, Y-chromosome microdeletions and pituitary disease are also diagnoses, not supplement targets. A man with a semen analysis outside the reference limits needs an examination and a hormonal panel before he needs shilajit.

Testosterone replacement is the wrong tool for a man who wants children. Sperm production depends on intratesticular testosterone at concentrations far above those in blood, driven by LH and FSH. Exogenous testosterone raises the blood level, the pituitary switches off, intratesticular testosterone collapses, and spermatogenesis stops — reliably enough that it has been studied as a contraceptive. Most men recover within a year of stopping; not all. The Endocrine Society guideline recommends against starting testosterone in men planning fertility in the near term, and the alternatives that preserve sperm production — hCG, clomiphene — are a specialist's prescription. The full reasoning is in When Lifestyle Isn't Enough: The TRT Decision Framework.

The partner's evaluation matters as much. Infertility is a diagnosis made on a couple. Optimising a semen analysis for six months while a partner's tubal or ovulatory problem goes unexamined is optimising the wrong variable. Twelve months of trying without conception — six if the partner is over 35 — is the point at which both people need a fertility clinic, regardless of any protocol.

Reading a Semen Analysis

The entire protocol is judged on one test, so the test needs to be understood.

In 2021 the WHO published the sixth edition of its laboratory manual, and the reference distribution underneath it came from an analysis of more than 3,500 fertile men from twelve countries on five continents. The fifth-centile values — the point below which only 5% of men who had recently fathered a child fell — are the "lower reference limits" that a laboratory report flags:

Two cautions come with that table, both from the paper that produced it. First, these values do not represent distinct limits between fertile and subfertile men — a man at 14 million/mL is not infertile, and a man at 40 million/mL is not guaranteed fertile. Second, the manual itself moved away from the word "threshold" toward "decision limits" precisely because a single cut-off invites over-interpretation. A semen analysis is a distribution, not a verdict.

Two practical rules follow. Always compare like with like: the same laboratory, the same abstinence interval (two to seven days), the same time of day. And never judge on one sample. Sperm parameters vary substantially between ejaculates from the same man, which is why a baseline should ideally be two analyses a few weeks apart, and why the week-12 comparison needs the same care.

The Layer Map

The protocol is graded C to its weakest load-bearing claim. CoQ10 would be a B on its own; the two botanicals rest on single-centre pilots, and a stack built on them cannot be graded higher than they are.

Layer 0 — What Actually Moves Sperm Counts

Almost everything with a large effect in male fertility is on this layer, and almost none of it is sold.

Body fat. A collaborative meta-analysis of 21 studies and 13,077 men found a J-shaped relationship between BMI and low sperm count. Against normal-weight men, the odds of oligozoospermia or azoospermia were 1.11 (95% CI 1.01–1.21) for overweight, 1.28 (1.06–1.55) for obese, and 2.04 (1.59–2.62) for morbidly obese men. Weight loss also reverses obesity-related low testosterone, which makes it the one Layer 0 lever that serves both the fertility and hormone routes.

Sleep, heat and alcohol. One week of five-hour nights cut daytime testosterone 10–15% in young men, and most testosterone release happens during sleep. Scrotal heat is an established stressor of spermatogenesis in the experimental literature; the human precautions — no laptop on the lap, no daily hot tub or sauna, loose underwear — cost nothing for twelve weeks. Alcohol's effect is concentrated in heavy, disordered drinking; the pooled observational data show no significant testosterone difference at moderate intake.

Vitamin D — to a level. The best trial here is a Copenhagen triple-blind RCT in 330 infertile men with 25(OH)D at or below 50 nmol/L, given 300,000 IU then 1,400 IU daily with calcium for 150 days. Vitamin D did not change semen parameters. Spontaneous pregnancies trended higher (7.3% vs 2.4%, CI crossing zero), and in the oligozoospermic subgroup live birth was higher (35.6% vs 18.3%) — a subgroup signal the authors themselves said needs verification. The honest reading: correct a deficiency because it is a deficiency, and do not expect the semen analysis to move because of it. Dose to a 25(OH)D above 50 nmol/L per the vitamin D dosing guide.

Zinc — only if low. The largest supplement trial ever run in male infertility is the reason zinc is conditional. FAZST randomised 2,370 men from couples planning fertility treatment to 30 mg zinc plus 5 mg folic acid or placebo for six months. Live birth: 34% versus 35% (risk difference −0.9%, 95% CI −4.7% to 2.8%). Concentration, motility, morphology, volume and total motile count: not significantly different. DNA fragmentation: higher on supplementation (29.7% vs 27.2%, mean difference 2.4%). Gastrointestinal side effects were about twice as common. A 2025 meta-analysis of 50 supplement RCTs found no convincing evidence of any supplement improving pregnancy or live birth, and rated the certainty of evidence for the sperm-parameter effects low or very low.

Zinc corrects zinc deficiency, and deficiency suppresses testosterone. That is the entire case. Measure serum zinc; supplement 15 mg if it is low; leave it out if it is not.

Layer 1 — Spermatogenesis Support, Judged at Twelve Weeks

Why twelve weeks

The developmental journey from spermatogonial stem cell to sperm in the ejaculate runs, in the textbook estimate, roughly ten to eleven weeks — and the most thorough modern review of human spermatogenesis argues that the accepted figure, which rests on a 1960s data set, may itself be in error by about six days. Epididymal transit adds to that. The sperm in a sample given today began developing in the previous season.

Every trial in this layer ran 90 days for that reason. A man who retests at week 6 is measuring the cycle that finished before he started, and will conclude — wrongly, in either direction — that the protocol did or did not work.

CoQ10 — 200 mg/day with a fatty meal (grade B)

Seminal oxidative stress is one of the better-established contributors to poor sperm quality, and CoQ10 is the antioxidant with the most randomised evidence.

A 2025 meta-analysis in the World Journal of Men's Health pooled nine RCTs in 781 men with idiopathic infertility. CoQ10 improved sperm concentration by 10.22 million/mL (95% CI 3.51–16.93), total motility by 4.95 percentage points (1.15–8.75), semen volume by 0.17 mL, and seminal CoQ10 levels. Clinical pregnancy odds were significantly higher (OR 6.02, 95% CI 1.97–18.41 — a wide interval, reflecting few events). Sperm morphology improved only in trials longer than three months. Three studies reported no adverse effects; one reported mild, transient ones.

A second 2025 meta-analysis of eight RCTs (877 men) agreed on total count, total and progressive motility and normal forms, and additionally found higher serum testosterone and inhibin B with lower LH and FSH — the hormonal signature of improved testicular function. It found no significant effect on sperm concentration, and flagged substantial heterogeneity across the semen-parameter trials.

Two meta-analyses that agree on motility and morphology and disagree on concentration is an honest picture of a modest, real effect. The subgroup finding on duration is the operational rule: CoQ10 is a twelve-week minimum, and the CoQ10 profile covers the ubiquinol-versus-ubiquinone question.

Shilajit — 100 mg twice daily, purified (grade C)

Shilajit's best trial is in exactly this population. Thirty-five oligospermic men (below 20 million/mL) took processed shilajit 100 mg twice daily after meals for 90 days; 28 completed. Against baseline: total sperm count +61.4%, motility +12.4–17.4% across the time intervals measured, normal forms +18.9%, serum testosterone +23.5% (all P < 0.001), and semen malondialdehyde — the oxidative stress marker — −18.7%. Liver and kidney panels were unchanged.

Three things temper it. There was no placebo group — 28 men were compared to their own baselines, in a population selected for low counts, where regression to the mean is guaranteed to flatter the result. The trial and the only placebo-controlled shilajit study (testosterone in men 45–55, 250 mg twice daily, significant but with no effect size reported) come from the same Kolkata institution and the same manufacturer's product. And no independent group has replicated either.

The other constraint is chemistry. Shilajit is a humic exudate that carries whatever the rock contained, and raw resin has documented heavy-metal contamination. Only purified, batch-tested product with a certificate of analysis for lead, arsenic, cadmium and mercury belongs in this protocol. The shilajit profile sets out the product-selection rules.

Ashwagandha — 675 mg/day in three doses (grade C)

A 46-man pilot randomised oligospermic men (below 20 million/mL) to full-spectrum ashwagandha root extract 675 mg/day in three doses, or placebo, for 90 days. Sperm count rose from 9.59 to 25.61 million/mL (+167%), semen volume from 1.74 to 2.76 mL (+53%), and motility from 18.62% to 29.19% (+57%), all P < 0.0001, with minimal change on placebo.

The percentages are large because the baseline was very low: a rise to 25.61 million/mL lands just above the WHO 2021 lower limit. It is one pilot, from one centre, using one extract, and it has not been replicated. Ashwagandha also carries rare hepatotoxicity reports, so ALT and AST at baseline and week 12 are part of the monitoring, and any jaundice or dark urine stops it.

The 675 mg regimen is different from the 600 mg KSM-66 dose used for cortisol in the ashwagandha profile; this is the dose the fertility trial used, and there is no basis for assuming the two are interchangeable.

Layer 2 — Libido and Erectile Function

Maca is the one compound with placebo-controlled evidence that sexual desire can improve independently of testosterone. A 12-week trial in men aged 21–56 randomised to gelatinised maca 1,500 mg, 3,000 mg, or placebo found improved self-reported sexual desire from week 8, with serum testosterone and oestradiol unchanged, and logistic regression showing the effect was independent of Hamilton depression and anxiety scores.

In 50 men with mild erectile dysfunction, 2,400 mg/day of dry extract for 12 weeks raised the IIEF-5 score by 1.6 ± 1.1 points against 0.5 ± 0.6 on placebo (P < 0.001), with larger gains on the psychological, physical and social subscales of a well-being questionnaire. The authors described it as a small but significant effect, which it is.

Maca has no semen-parameter data and contributes nothing to Layer 1. It is here because libido and erection are half the outcome set, and because it is the one item on this page a man is likely to notice. Moderate or severe erectile dysfunction is a vascular symptom — often an early cardiovascular one — that needs a clinician; PDE5 inhibitors outperform every supplement, and the peptide route is a separate protocol in The Sexual Wellness Protocol.

The Twelve-Week Schedule

Week 0 — Baseline. Semen analysis (ideally two, a few weeks apart, same laboratory, 2–7 days' abstinence). Fasting 08:00–10:00 testosterone, SHBG, LH, FSH. 25(OH)D, serum zinc, ALT/AST. Weight and waist. IIEF-5 if Layer 2 is planned. Book the urologist if any semen parameter is below the reference limit or any hormone is abnormal.

Weeks 0–2 — Layer 0 only. Start vitamin D if 25(OH)D is below 50 nmol/L; zinc 15 mg if serum zinc is low. Sleep seven to eight hours. Remove heat sources. Reduce alcohol to occasional. Begin the weight-loss plan if BMI is over 30 — this is the highest-leverage item in the entire protocol.

Week 2 — Add Layer 1. CoQ10 200 mg, purified shilajit 100 mg twice daily, ashwagandha 225 mg three times daily. All with food.

Week 4 — Optionally add Layer 2. Maca 2,400 mg in the morning.

Weeks 4–12 — Run it. Do not retest semen. Keep the sleep, heat and alcohol variables fixed, because a change in any of them at week 8 will be indistinguishable from a supplement effect at week 12.

Week 8 — IIEF-5 if on maca. Desire effects appeared from week 8 in the trial.

Week 12 — Judgement. Repeat semen analysis, same laboratory, same abstinence interval. Repeat 25(OH)D, zinc, ALT/AST, hormone panel. Compare against the baseline, not against how things feel.

Record everything in the biomarker tracker; a week-12 comparison against memory is not a comparison.

Exit Criteria — Decide These at Week 0

• Azoospermia or a concentration below 5 million/mL at baseline — this needs genetic testing and a hormonal work-up now, not a 12-week trial of antioxidants
• Low testosterone with low or normal LH and FSH — secondary hypogonadism needs prolactin and a pituitary evaluation; the decision framework is in the TRT article
• Any scrotal mass, pain or asymmetry — examination
• Week-12 semen analysis unchanged or worse — the protocol has had its fair run. Stop layering; refer
• Twelve months of trying (six if the partner is over 35) — the couple goes to a fertility clinic whatever the numbers say
• A partner starting assisted reproduction — the treating clinic decides what the man takes during a cycle, not this page

What This Protocol Deliberately Excludes

The Tongkat Ali, Fadogia and boron stack. That is the testosterone route — free testosterone via SHBG reduction, LH support, cortisol modulation — and it is well built in the Hormonal Optimization Stack and the Boron + Tongkat Ali guide. It is excluded here not because it is wrong but because it targets a different number. A man whose semen analysis is normal and whose complaint is a low testosterone reading should use that protocol, not this one. Fadogia specifically has no human data and no place in a fertility context, where testicular safety is the whole point.

Testosterone replacement. Excluded for the reason given at the top: it stops spermatogenesis.

Routine zinc and folic acid. Excluded on the strength of a 2,370-man trial.

Multi-ingredient "fertility blends." Undisclosed doses, usually including zinc and folic acid at the FAZST doses, and no way to attribute a change at week 12 to anything.

Heat-based, device-based or "testicular" interventions sold online. No trial evidence; some plausible harm.

Frequently Asked Questions

Can I run this alongside the Hormonal Optimization Stack?

Not sensibly. The two protocols overlap on zinc and ashwagandha, differ on everything else, and are judged on different endpoints. Running both makes any week-12 change unattributable. Choose by the number you are trying to move: semen analysis here, testosterone panel there.

My semen analysis is normal but my libido is low. Do I need Layer 1?

No. Layer 1 is spermatogenesis support and does nothing for desire. Layer 0 plus maca is the rational subset — and a normal semen analysis with low desire and low morning testosterone is a reason to read the TRT decision framework rather than to add supplements.

Is CoQ10 enough on its own?

For a man with idiopathic infertility who wants the single best-supported supplement, yes — it is the only Layer 1 compound with meta-analytic evidence, and two meta-analyses agree on motility and morphology. Shilajit and ashwagandha are additions with weaker evidence, not requirements.

Why not judge at six weeks if I feel different?

Because the sperm being counted at six weeks began developing before the protocol started. Feeling different is a Layer 2 effect and is judged on the IIEF-5. Layer 1 is judged on a number that physically cannot respond before the cycle completes.

What if the week-12 analysis is better — do I keep going?

Continue to conception or to the next review, retesting every three months, and keep the Layer 0 variables fixed. The evidence base for any of these compounds beyond 90 days is thin, so continuation is a judgement rather than a trial result.

Does shilajit raise testosterone as well?

The one placebo-controlled trial found significantly higher total and free testosterone in men 45–55 at 250 mg twice daily, without reporting the size of the effect. Its fertility data are stronger than its testosterone data, which is why it is here and not in the testosterone stack.

Related Research

• The Male Vitality Protocol
• When Lifestyle Isn't Enough: The TRT Decision Framework
• Natural Testosterone Optimization: What Actually Works (and What Doesn't)
• Shilajit (Purified)
• Hormonal Optimization Stack